"The integration of MRI with adaptive radiotherapy represents the next generation in radiation oncology and a potential new standard of care for treating cancer," said Dr. Steinberg. "The patient, clinical and economic benefits associated with MRI-guided radiotherapy make it highly attractive to a multitude of stakeholders."
An audio webcast of the meeting is available on the investor relations section of ViewRay's website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.
Ad Statistics
Times Displayed: 111469
Times Visited: 6692 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology helping to transform radiation therapy, resulting in improved treatment outcomes that benefit both patients and health care systems around the world. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Back to HCB News
